Patents by Inventor Wieslaw Adam Mazur
Wieslaw Adam Mazur has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20140179875Abstract: Described herein are novel solid-supported sulfurization reagents having the general structure: (I) wherein (P) is a polymer; X is a linker; R1 is an alkyl group, a cycloalkyl group, an aryl group, or a heterocycle; and R2 is an alkyl group, an aryl group, a methyleneacyloxy group having the formula —CH2—O—C(O)—R7, a methylene carbonate group having the formula —CH2—O—C(O)—OR8, or a methylene carbamate group having the formula —CH2—O—C(O)—NR9R10, wherein R7 is a C1 to C20 hydrocarbon residue, R8 is any alkyl, cycloalkyl, aryl, or heteroaryl, and R9 and R10 are independently hydrogen, alkyl, cycloalkyl, aryl, or heteroaryl. Other embodiments include solid-supported sulfurization reagents having the structure of Formula I, wherein (P) is a polystyrene-based solid support and X is an aromatic linker. Also described herein are methods for synthesizing the solid-supported sulfurization reagents and their use during the synthesis of oligonucleotides.Type: ApplicationFiled: July 24, 2012Publication date: June 26, 2014Applicant: GIRINDUS AMERICA, INC.Inventors: Wieslaw Adam Mazur, Victor Sorokin, Steven Karl Laughlin
-
Patent number: 8710210Abstract: A method for synthesizing an oligonucleotide which comprises using a sulfurizing agent of general formula (I) for sulfurizing at least one phosphorus internucleotide linkage of a precursor of the oligonucleotide, wherein R is an aryl group or a heteroaryl group, which is bonded to the S-atom through an annular carbon atom; and R1 and R2 are independently organic residues, preferably a C1-C20 hydrocarbon residue. The method may further comprise purifying the oligonucleotide. Also included is a process for the synthesis of the sulfurizing agent.Type: GrantFiled: June 30, 2011Date of Patent: April 29, 2014Assignee: Girindus America, Inc.Inventors: Yigang He, Victor Sorokin, Wieslaw Adam Mazur
-
Patent number: 8586973Abstract: The present invention relates to a host material comprising a compound having two carbazole moieties which is suitable for blue-emitting OLEDs. Surprisingly, it has been found that when appropriate substituents are present in the carbazole structure, the solubility of the compounds can be improved without any adverse effect on the OLED performance. The present invention further relates to the use of the host materials and to an organic light emitting device comprising the host material.Type: GrantFiled: October 15, 2009Date of Patent: November 19, 2013Assignee: Solvay SAInventors: Roland Martin, Veronique Mathieu, Victor Sorokin, Praveen Bachawala, Wieslaw Adam Mazur, Jonathan Maunoury
-
Publication number: 20130096291Abstract: A method for synthesizing an oligonucleotide which comprises using a sulfurizing agent of general formula (I) for sulfurizing at least one phosphorus internucleotide linkage of a precursor of the oligonucleotide, wherein R is an aryl group or a heteroaryl group, which is bonded to the S-atom through an annular carbon atom; and R1 and R2 are independently organic residues, preferably a C1-C20 hydrocarbon residue. The method may further comprise purifying the oligonucleotide. Also included is a process for the synthesis of the sulfurizing agent.Type: ApplicationFiled: June 30, 2011Publication date: April 18, 2013Applicant: GIRINDUS AMERICA, INC.Inventors: Yigang He, Victor Sorokin, Wieslaw Adam Mazur
-
Publication number: 20120071640Abstract: An oligonucleotide which comprises at least one internucleotide linkage comprising a P—S—R bond and at least two nucleosides, wherein R corresponds to the formula (I) wherein A is a geminally substituted alkylene group, preferably CH2, X and Y are independently selected from S and O, and R0 is selected from the group consisting of optionally substituted carbon bonded organic residue, such as in particular optionally substituted alkyl or aryl, SRx, ORx and NRxRy wherein Rx and/or Ry are selected from H and organic residues and at least Rx is a substituent other than H. Another object of the invention is a sulfurizing agent useful for oligonucleotide manufacture and the manufacture thereof.Type: ApplicationFiled: June 22, 2011Publication date: March 22, 2012Applicant: GIRINDUS AMERICA, INC.Inventors: Wieslaw Adam MAZUR, Yigang HE, Victor D. SOROKIN
-
Publication number: 20110260149Abstract: The present invention relates to a host material comprising a compound having a carbazole moiety which is suitable for blue-emitting OLEDs. Surprisingly, it has been found that when appropriate substituents are present in the carbazole structure, the solubility of the compounds can be improved without any adverse effect on the OLED performance. The present invention further relates to the use of the host materials and to an organic light emitting device comprising the host material.Type: ApplicationFiled: October 15, 2009Publication date: October 27, 2011Applicant: SOLVAY SAInventors: Roland Martin, Veronique Mathieu, Victor Sorokin, Praveen Bachawala, Wieslaw Adam Mazur
-
Publication number: 20110198579Abstract: The present invention relates to a host material comprising a compound having two carbazole moieties which is suitable for blue-emitting OLEDs. Surprisingly, it has been found that when appropriate substituents are present in the carbazole structure, the solubility of the compounds can be improved without any adverse effect on the OLED performance. The present invention further relates to the use of the host materials and to an organic light emitting device comprising the host material.Type: ApplicationFiled: October 15, 2009Publication date: August 18, 2011Applicant: SOLVAY SAInventors: Roland Martin, Veronique Mathieu, Victor Sorokin, Praveen Bachawala, Wieslaw Adam Mazur, Jonathan Maunoury
-
Patent number: 7897731Abstract: Isolated corticotropin releasing factor derivatives, and nucleic acids encoding the same, are effective for treating corticotropin releasing factor 2 receptor modulated disorders such as muscular dystrophy.Type: GrantFiled: October 26, 2009Date of Patent: March 1, 2011Assignee: Warner Chilcott Company, LLCInventors: Robert Joseph Isfort, Wieslaw Adam Mazur
-
Publication number: 20100244012Abstract: The present invention relates to anthracene derivative compounds represented by Formula I: or a pharmaceutically acceptable salt thereof, with R1, R2, R3, R4, L, X, a, b, and c defined herein. The compounds of the present invention, having a substituted silicon atom introduced in anthracene, advantageously improve the solubility of anthracene without any adverse effects, thereby allowing solvent-processing. Also disclosed are light emitting materials comprising such compounds, the use of such light emitting materials, and organic light emitting devices comprising such light emitting materials.Type: ApplicationFiled: December 18, 2008Publication date: September 30, 2010Applicant: SOLVAY (SOCIETE ANONYME)Inventors: Wieslaw Adam Mazur, Angelina Tsenova Georgieva
-
Publication number: 20100197579Abstract: Isolated corticotropin releasing factor derivatives, and nucleic acids encoding the same, are effective for treating corticotropin releasing factor 2 receptor modulated disorders such as muscular dystrophy.Type: ApplicationFiled: October 26, 2009Publication date: August 5, 2010Inventors: Robert Joseph Isfort, Wieslaw Adam Mazur
-
Patent number: 7632933Abstract: Isolated corticotropin releasing factor derivatives, and nucleic acids encoding the same, are effective for treating corticotropin releasing factor 2 receptor modulated disorders such as muscular dystrophy.Type: GrantFiled: February 2, 2007Date of Patent: December 15, 2009Assignee: The Procter & Gamble CompanyInventors: Robert Joseph Isfort, Wieslaw Adam Mazur
-
Patent number: 7612080Abstract: The preferred embodiments generally relate to methods and compositions that affect the GTP-binding activity of members of the Rho family GTPases, preferably Rac (Rac1, Rac2 and/or Rac3), such compositions include compounds that modulate the GTP/GDP exchange activity, along with uses for the compounds including screening for compounds which recognize Rac GTPase, and methods of treating pathological conditions associated or related to a Rho family GTPase, including Rac. The preferred embodiments also relate to methods of using such compounds, or derivatives thereof, e.g., in therapeutics, diagnostics, and as research tools.Type: GrantFiled: November 18, 2005Date of Patent: November 3, 2009Assignee: Cincinnati Children's Hospital Medical CenterInventors: Yi Zheng, Huzoor Akbar, David A. Williams, Wieslaw Adam Mazur
-
Patent number: 7608701Abstract: Isolated corticotropin releasing factor derivatives, and nucleic acids encoding the same, are effective for treating corticotropin releasing factor 2 receptor modulated disorders such as muscular dystrophy.Type: GrantFiled: February 2, 2007Date of Patent: October 27, 2009Assignee: The Procter & Gamble CompanyInventors: Robert Joseph Isfort, Wieslaw Adam Mazur
-
Publication number: 20090124793Abstract: Isolated corticotropin releasing factor derivatives, and nucleic acids encoding the same, are effective for treating corticotropin releasing factor 2 receptor modulated disorders such as muscular dystrophy.Type: ApplicationFiled: February 2, 2007Publication date: May 14, 2009Inventors: Robert Joseph Isfort, Wieslaw Adam Mazur
-
Patent number: 7462597Abstract: Isolated corticotropin releasing factor derivatives, and nucleic acids encoding the same, are effective for treating corticotropin releasing factor 2 receptor modulated disorders such as muscular dystrophy.Type: GrantFiled: May 4, 2005Date of Patent: December 9, 2008Assignee: The Procter & Gamble CompanyInventors: Robert Joseph Isfort, Wieslaw Adam Mazur
-
Patent number: 7192923Abstract: Isolated corticotropin releasing factor derivatives, and nucleic acids encoding the same, are effective for treating corticotropin releasing factor 2 receptor modulated disorders such as muscular dystrophy.Type: GrantFiled: December 11, 2002Date of Patent: March 20, 2007Assignee: The Procter & Gamble CompanyInventors: Robert Joseph Isfort, Wieslaw Adam Mazur
-
Patent number: 7192924Abstract: Isolated corticotropin releasing factor derivatives, and nucleic acids encoding the same, are effective for treating corticotropin releasing factor 2 receptor modulated disorders such as muscular dystrophy.Type: GrantFiled: December 11, 2002Date of Patent: March 20, 2007Assignee: The Procter & Gamble CompanyInventors: Robert Joseph Isfort, Wieslaw Adam Mazur
-
Patent number: 7132539Abstract: The present invention relates to compounds which comprise a nitrogen-containing ring scaffold substituted by an R1 alkyl units selected from the group consisting of C1–C12 linear or branched alkyl, C3–C8 cyclic alkyl, C2–C12 linear or branched alkenyl, or haloalkyl, for example, the 2-keto-3-alkylpiperazines having the formula: wherein R is selected from the group consisting of phenyl, 3-fluorophenyl, 4-fluorophenyl, 3,5-difluorophenyl, and 4-chlorophenyl; R1 is selected from the group consisting of methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, sec-butyl, tert-butyl, cyclopropyl, cyclopropylmethyl, cyclopentyl, cyclopentylmethyl, cyclohexyl, cyclohexylmethyl, benzyl, allyl, 1-methylallyl, 2-methylallyl, but-2-enyl, and propargyll; R7a is selected from the group consisting of hydrogen, —CO2H, —CONH2, —CONHCH3, and —CON(CH3)2; R8 is benzyl, substituted benzyl, or naphthalen-2-ylmethyl.Type: GrantFiled: October 20, 2003Date of Patent: November 7, 2006Assignee: The Procter & Gamble CompanyInventors: Frank Hallock Ebetino, Xinrong Tian, Wieslaw Adam Mazur, Anny-Odile Colson
-
Patent number: 7087759Abstract: Disclosed are MC-3/MC-4 receptor ligands, the ligands having the following formula: wherein A is a conformationally restricted ring system selected from the group consisting of: a) non-aromatic carbocyclic rings; b) aromatic carbocyclic rings; c) non-aromatic heterocyclic rings; d) aromatic heterocyclic rings; wherein said rings comprises from 5 to 8 atoms; and W is a unit which preferable comprises D-1-fluorophenyalanine, Y comprises a heteroatom, and Z comprises an aromatic carbocyclic ring. Also disclosed are pharmaceutical compositions comprising the ligands of the invention as well as methods of treating diseases mediated through MC-3/MC-4 receptors.Type: GrantFiled: May 28, 2004Date of Patent: August 8, 2006Assignee: The Procter & Gamble CompanyInventors: Wieslaw Adam Mazur, Xinrong Tian, Xiufeng Eric Hu, Frank Hallock Ebetino
-
Patent number: 6936585Abstract: Isolated corticotropin releasing factor derivatives, and nucleic acids encoding the same, are effective for treating corticotropin releasing factor 2 receptor modulated disorders such as muscular dystrophy.Type: GrantFiled: December 11, 2002Date of Patent: August 30, 2005Assignee: The Procter & Gamble CompanyInventors: Robert Joseph Isfort, Wieslaw Adam Mazur